When you use our sites, PAREXEL will assign cookie files (“Cookies”) to you, which are a small amount of information we send to your web browser. Cookies enable the computers operating our websites to differentiate between visitors and to track the patterns of activities engaged in by different visitors. By clicking the Continue Browsing button or continuing to use this site, you agree to accept the PAREXEL Privacy Policy and all Cookies deployed on this site. You may choose to continue browsing with cookies, or leave the site.

I think the QSI acquisition is going to help benefit our clients. First of all, this is an up and running company with significant scale. They already serve some of the world’s largest pharmaceutical companies. They are extremely effective and efficient in the way they run their operation and so we are really excited about bringing those efficiencies and benefits to our customers.
I think it’s worth mentioning what the benefits of the QSI acquisition could be for our customers. All of our customer base is really under pressure to perform better just like any company from a financial perspective to the degree there are opportunities to reduce costs while delivering the necessary services with quality-that’s an opportunity for outsourcing. When you look at pharmacovigilance and particularly the QSI capabilities, we believe, with the scale that we now have, we can deliver these services far more efficiently than any one company could do on their own. We also benefit from the efficiencies that come from the fact that the operations are executed in India.
I think the QSI acquisition helps our clients along their journey to bring products to market. Pharmacovigilance plays a very important role during the drug development process itself but then once products are in the marketplace, pharmacovigilance is critical in order to ensure that the products are safe and that that safety holds up as larger and larger populations are exposed to a particular innovative treatment in the marketplace.